18 results
DEF 14A
CMRA
Comera Life Sciences Holdings, Inc.
11 Aug 23
Definitive proxy
4:15pm
. Rev. Dr. Sherblom is an independent director as defined by applicable Nasdaq (as defined below) market standards governing the independence … firm.
CORPORATE GOVERNANCE
Board and Committee Matters
Board Leadership and Independence. We have structured our corporate governance in a manner
PRE 14A
CMRA
Comera Life Sciences Holdings, Inc.
1 Aug 23
Preliminary proxy
5:08pm
standards governing the independence of directors, and he has consented to serve, if elected. If Rev. Dr. Sherblom is unable to serve, proxies … independent registered public accounting firm.
CORPORATE GOVERNANCE
Board and Committee Matters
Board Leadership and Independence. We have structured
8-K
EX-99.1
CMRA
Comera Life Sciences Holdings, Inc.
1 Aug 23
Comera Life Sciences Announces $4.1 Million
4:08pm
of life by offering treatments that support greater independence,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera
424B3
CMRA
Comera Life Sciences Holdings, Inc.
31 Mar 23
Prospectus supplement
4:34pm
and Edward Sullivan; and our Class III directors consist of Roopom Banerjee, MPP, Kirsten Flowers and William A. Wexler.
Director Independence … to audit our financial statements;
helping to ensure the independence and performance of the independent registered public accounting firm;
discussing
424B3
CMRA
Comera Life Sciences Holdings, Inc.
31 Mar 23
Prospectus supplement
4:34pm
A. Wexler.
Director Independence
Under Nasdaq listing standards, a majority of the members of the Holdco Board must qualify as “independent … registered public accounting firm to audit our financial statements;
helping to ensure the independence and performance of the independent registered public
424B3
d70engb003eh
31 Mar 23
Prospectus supplement
4:32pm
8-K
EX-99.1
heg5rx7
10 Nov 22
Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights
4:32pm
424B3
9c1qwf7linfwbw18n9b
15 Sep 22
Prospectus supplement
4:09pm
8-K
EX-99.1
00d6vm8
15 Aug 22
Comera Life Sciences Provides Business Highlights and Reports Financial Results for the Second Quarter 2022
4:08pm
424B3
ukd tjdeiq
28 Jun 22
Prospectus supplement
10:45am
8-K
4zj8ctkar be5
25 May 22
Index to Financial Statements
5:23pm
S-1
gy9u9b
4 May 22
IPO registration
9:23pm
S-4
EX-10.7
j1jxotj7
8 Mar 22
Registration of securities issued in business combination transactions
9:49pm
S-4
EX-10.9
zpobemv1ate
8 Mar 22
Registration of securities issued in business combination transactions
9:49pm
425
35nylz7vp1drbkbrn
8 Feb 22
Business combination disclosure
4:43pm
- Prev
- 1
- Next